Skip to main content
OpenTrials
Completed

NCT Number: NCT03274960

Screening and Treating Asymptomatic Bacteriuria Every Trimester and Preterm Birth

This study is evaluating whether screening of a pregnant woman for asymptomatic bacteriuria in each trimester for early detection and treatment of bacteriuria will reduce the incidence of preterm birth in Harare.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Zimbabwe

Harare, Metropolitan, +263, Zimbabwe

About this study

Asymptomatic bacteriuria is common in pregnancy. If the disease is not detected early in pregnancy and treated it often progresses to an acute symptomatic disease, pyelonephritis which is associated with adverse pregnancy outcomes including preterm birth.

It is recommended that every woman be screened for asymptomatic bacteriuria by urine culture test at initial antenatal care visit so that the disease is if identified is treated early to prevent preventable complications of the disease in pregnancy. Culture test is expensive and therefore unavailable at several primary care settings especially in low resource settings where majority of pregnant women register and visit for antenatal care. In Zimbabwe antenatal care at primary care clinics is not including screening for asymptomatic bacteriuria. Majority who present with symptoms are empirically treated.

In this study the Griess nitrite test, an effective inexpensive screening test for asymptomatic bacteriuria is used. the test detects nitrite in urine which is associated with presence of nitrate reducing uropathogens, commonly the gram negative bacteria. All the positive samples will then be further tested by culture for bacteria identification, quantification and antibiotic sensitivity. A Randomized controlled trial research design is being used. participants are randomly allocated to intervention group or control group. Urine samples will be collected and tested 3 times for each recruited participant in the intervention arm. treatment will be initiated for positive result according to sensitivity test. Control group will only be subjected to routine existing antenatal care.

Participants will be recruited before 22 weeks gestation and followed on for second contact by 28 weeks and third contact by 36 weeks. Follow up will be stopped on delivery for noting gestation at delivery, whether preterm or term.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women registering at study site.
  • Woman is able to identify her date of last menstrual period.
  • Gestation of pregnancy is between 6 and 22 weeks.
  • Woman is asymptomatic for bacteriuria
  • Woman voluntarily signs the consent form

Exclusion criteria

  • Pregnant woman ill and unwell
  • Pregnant woman unwilling to sign consent form
  • Woman who had antibiotic treatment 2 weeks before recruitment
  • Woman on long term antibiotic treatment
  • Woman who fails to identify date of last menstrual period
  • Woman symptomatic for urinary tract infection

Treatment and study plan

Griess,

Combination Product

Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.

Other names: Culture, Treatment

Primary outcomes

  1. Preterm birth

    Time frame: Preterm birth will be calculated as gestation at birth of baby using date of birth and the first date of last menstrual period.

    Preterm birth will be delivery of a baby before 37 complete weeks of gestation from the first date of last menstrual period. It will be sub-categorized as extremely preterm (<28 weeks), very preterm (28 to <32 weeks) and moderate to late preterm (32 to <37 weeks).

Secondary outcomes

  1. symptomatic bacteriuria

    Time frame: The symptoms will be noted at interviews at follow up after every 6 to 8 weeks from previous contact.

    Noted from history of urinary tract symptoms which include pain on micturition, fever, blood in urine, increased urine frequency, foul smelling urine and cloudy urine.

  2. Isolated uropathogen

    Time frame: These will be available at recruitment by 22 weeks, between 22 and 28 weeks at second screening and at 28 to 36 weeks at the third screening.

    All isolated bacterial species from urine sample identified from culture test. These are bacteria identified to be responsible for asymptomatic bacteriuria.

  3. Antibiotic sensitivity

    Time frame: These will be available at recruitment by 22 weeks, between 22 and 28 weeks at second screening and at 28 to 36 weeks at the third screening

    from urine culture results identified antibiotics sensitive for treatment of isolated bacteria will be noted.

  4. Gestation at birth

    Time frame: Gestation will be calculated at delivery of baby.

    Gestation is the calculated total number of weeks from first date of last menstrual period to the date of delivery.

Sponsors and collaborators

Lead sponsor

University of Zimbabwe

Other

Registry information

Official study title

The Effect of Screening and Treatment of Asymptomatic Bacteriuria Every Trimester During Pregnancy on Incidence of Preterm Birth in Harare, Zimbabwe

Acronym: Pretermbirth

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Sep 7, 2017
Registry last updated
May 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.